Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer

Gynecologic Oncology

Volumn 127, Issue 3, 2012, Pages 579-586

  Wilson, Andrew J ^a   Lalani, Anum S ^a   Wass, Erika ^a   Saskowski, Jeanette ^a   Khabele, Dineo ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Depsipeptide (FK228); Histone deacetylase inhibitors (HDACi); Ovarian cancer; pH2AX; Romidepsin

Indexed keywords

CASPASE 3; CISPLATIN; ROMIDEPSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CANCER; OVARY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DEPSIPEPTIDES; DNA DAMAGE; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 84868517231     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.09.016     Document Type: Article

References (38)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 1 Jan 2012 10 29
2. F. Muggia Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer Gynecol Oncol 112 1 Jan 2009 275 281
3. TCGA Integrated genomic analyses of ovarian carcinoma Nature 474 7353 Jun 30 2011 609 615 [Research Support, N.I.H., Extramural]
4. P.C. Fong, D.S. Boss, T.A. Yap, A. Tutt, P. Wu, and M. Mergui-Roelvink Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2 Jul 9 2009 123 134
5. A.J. Wilson, E. Holson, F. Wagner, Y.L. Zhang, D.M. Fass, and S.J. Haggarty The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells Cancer Biol Ther 12 6 Sep 15 2011 484 493 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]
6. R. Furumai, A. Matsuyama, N. Kobashi, K.H. Lee, M. Nishiyama, and H. Nakajima FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases Cancer Res 62 17 Sep 1 2002 4916 4921
7. R.L. Piekarz, R. Frye, M. Turner, J.J. Wright, S.L. Allen, and M.H. Kirschbaum Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma J Clin Oncol 27 32 Nov 10 2009 5410 5417
8. R.L. Piekarz, R. Frye, H.M. Prince, M.H. Kirschbaum, J. Zain, and S.L. Allen Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma Blood 117 22 Jun 2 2011 5827 5834 [Clinical Trial, Phase II Multicenter Study Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't]
9. W.M. Bonner, C.E. Redon, J.S. Dickey, A.J. Nakamura, O.A. Sedelnikova, and S. Solier GammaH2AX and cancer Nat Rev Cancer 8 12 Dec 2008 957 967 [Research Support, N.I.H., Intramural Review]
10. J.P. Banath, D. Klokov, S.H. MacPhail, C.A. Banuelos, and P.L. Olive Residual gammaH2AX foci as an indication of lethal DNA lesions BMC Cancer 10 2010 4
11. D. Khabele, D.S. Son, A.K. Parl, G.L. Goldberg, L.H. Augenlicht, and J.M. Mariadason Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy Cancer Biol Ther 6 5 May 2007 795 801 [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]
12. P.L. Lorenzi, W.C. Reinhold, S. Varma, A.A. Hutchinson, Y. Pommier, and S.J. Chanock DNA fingerprinting of the NCI-60 cell line panel Mol Cancer Ther 8 4 Apr 2009 713 724
13. O.N. Ikediobi, H. Davies, G. Bignell, S. Edkins, C. Stevens, and S. O'Meara Mutation analysis of 24 known cancer genes in the NCI-60 cell line set Mol Cancer Ther 5 11 Nov 2006 2606 2612
14. D.A. Scudiero, A. Monks, and E.A. Sausville Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen J Natl Cancer Inst 90 11 Jun 3 1998 862
15. C. DelloRusso, P.L. Welcsh, W. Wang, R.L. Garcia, M.C. King, and E.M. Swisher Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation Mol Cancer Res 5 1 Jan 2007 35 45
16. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, and D. Vistica New colorimetric cytotoxicity assay for anticancer-drug screening J Natl Cancer Inst 82 13 Jul 4 1990 1107 1112 [Comparative Study]
17. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
18. B. Rubio-Viqueira, and M. Hidalgo Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients Clin Pharmacol Ther 85 2 Feb 2009 217 221
19. A.J. Wilson, D.S. Byun, S. Nasser, L.B. Murray, K. Ayyanar, and D. Arango HDAC4 promotes growth of colon cancer cells via repression of p21 Mol Biol Cell 19 10 Oct 2008 4062 4075
20. A.J. Wilson, D. Arango, J.M. Mariadason, B.G. Heerdt, and L.H. Augenlicht TR3/Nur77 in colon cancer cell apoptosis Cancer Res 63 17 Sep 1 2003 5401 5407
21. A.J. Wilson, Y.Q. Cheng, and D. Khabele Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy J Ovarian Res 5 1 Apr 24 2012 12
22. D.S. Son, A.J. Wilson, A.K. Parl, and D. Khabele The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21 Cancer Biol Ther 9 11 Jun 2010 928 935 [Research Support, N.I.H., Extramural]
23. S. Bhaskara, B.J. Chyla, J.M. Amann, S.K. Knutson, D. Cortez, and Z.W. Sun Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control Mol Cell 30 1 Apr 11 2008 61 72
24. C. Conti, E. Leo, G.S. Eichler, O. Sordet, M.M. Martin, and A. Fan Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage Cancer Res 70 11 Jun 1 2010 4470 4480
25. S. Bhaskara, S.K. Knutson, G. Jiang, M.B. Chandrasekharan, A.J. Wilson, and S. Zheng Hdac3 is essential for the maintenance of chromatin structure and genome stability Cancer Cell 18 5 Nov 16 2010 436 447 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]
26. K. Ozaki, F. Kishikawa, M. Tanaka, T. Sakamoto, S. Tanimura, and M. Kohno Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs Cancer Sci 99 2 Feb 2008 376 384
27. V.L. Luchenko, C.D. Salcido, Y. Zhang, K. Agama, E. Komlodi-Pasztor, and R.F. Murphy Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer Cell Cycle 10 18 Sep 15 2011 3119 3128 [Research Support, N.I.H., Intramural]
28. M. Bots, and R.W. Johnstone Rational combinations using HDAC inhibitors Clin Cancer Res 15 12 Jun 15 2009 3970 3977 [Research Support, Non-U.S. Gov't Review]
29. S.C. Modesitt, and S.J. Parsons In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter? Gynecol Oncol 119 2 Nov 2010 351 357
30. J.H. Lee, M.L. Choy, L. Ngo, S.S. Foster, and P.A. Marks Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair Proc Natl Acad Sci U S A 107 33 Aug 17 2010 14639 14644 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]
31. J.J. Xiao, Y. Huang, Z. Dai, W. Sadee, J. Chen, and S. Liu Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4, 21-diisopropyl-2-oxa-12,13-dithi a-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16- ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines J Pharmacol Exp Ther 314 1 Jul 2005 467 475 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]
32. J.J. Xiao, A.B. Foraker, P.W. Swaan, S. Liu, Y. Huang, and Z. Dai Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1 J Pharmacol Exp Ther 313 1 Apr 2005 268 276 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]
33. Y. Tabe, M. Konopleva, R. Contractor, M. Munsell, W.D. Schober, and L. Jin Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells Blood 107 4 Feb 15 2006 1546 1554
34. H. Kim, S.N. Kim, Y.S. Park, N.H. Kim, J.W. Han, and H.Y. Lee HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization Int J Oncol 38 3 Mar 2011 807 812 [Research Support, Non-U.S. Gov't]
35. K.C. Chao, C.C. Chang, M.S. Yen, and P.H. Wang Anti-tumor activity of histone deacetylase inhibitors and the effect on ATP-binding cassette in ovarian carcinoma cells Eur J Gynaecol Oncol 31 4 2010 402 410 [Research Support, Non-U.S. Gov't]
36. S. Hauswald, J. Duque-Afonso, M.M. Wagner, F.M. Schertl, M. Lubbert, and C. Peschel Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes Clin Cancer Res 15 11 Jun 1 2009 3705 3715 [Research Support, Non-U.S. Gov't]
37. K.K. To, O. Polgar, L.M. Huff, K. Morisaki, and S.E. Bates Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells Mol Cancer Res 6 1 Jan 2008 151 164
38. R.W. Robey, Z. Zhan, R.L. Piekarz, G.L. Kayastha, T. Fojo, and S.E. Bates Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176) Clin Cancer Res 12 5 Mar 1 2006 1547 1555 [Clinical Trial, Phase I Clinical Trial, Phase II Research Support, N.I.H., Intramural]